Announced
Completed
Synopsis
Eli Lilly and Company, a manufacturer of pharmaceutical products, completed the acquisition of Dermira, a biopharmaceutical company for $1.1bn. "We are pleased to complete the acquisition of Dermira, and look forward to continuing their important work to develop new therapeutic options for patients with chronic skin conditions," Patrik Jonsson, Lilly Senior Vice President.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.